
Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study
Summary
Lexeo Therapeutics has shared encouraging interim data from an early-stage clinical trial assessing its gene therapy for a specific inherited heart condition. The treatment significantly lowered the arrhythmia burden in trial participants. The company now intends to initiate a pivotal study for the therapy in the future.
Lexeo Therapeutics Inc. (NASDAQ:LXEO) on Monday announced positive interim results from its ongoing HEROIC-PKP2 Phase 1/2 trial evaluating LX2020 in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) and outlined plans to launch a pivotal study in late 2027. PKP2-ACM is an inherited heart muscle condition caused by a change, or variant, in the PKP2 gene. The clinical-stage genetic medicine company dosed 10 participants,…
Source: Read the full story at Top Stories Feed